Vigil Neuroscience, Inc. (VIGL)

Market Cap	98.01M
Revenue (ttm)	n/a
Net Income (ttm)	-84.26M
Shares Out	46.67M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,549
Open	1.970
Previous Close	1.920
Day's Range	1.970 - 2.240
52-Week Range	1.312 - 6.060
Beta	1.95
Analysts	Strong Buy
Price Target	16.33 (+677.62%)
Earnings Date	May 13, 2025

About VIGL

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company’s lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurode...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: VIGL
• Website: https://www.vigilneuro.com

Analyst Forecast

According to 5 analysts, the average rating for VIGL stock is "Strong Buy." The 12-month stock price forecast is $16.33, which is an increase of 677.62% from the latest price.

Price Target

$16.33

(677.62% upside)

Analyst Consensus: Strong Buy